6 research outputs found
Phase I extension clinical study of BB503, a first-in-class cancer stemness kinase inhibitor, in adult patients with advanced head and neck cancer.
No full textA phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
No full textA phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
No full textA phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.
No full text
